Literature DB >> 21212256

Morphine distribution in the spinal cord after chronic infusion in pigs.

Sean H Flack1, Christine M Anderson, Christopher Bernards.   

Abstract

BACKGROUND: Continuous intrathecal drug delivery provides new options for chronic delivery of drugs that target the spinal cord, but therapeutic efficacy is highly variable. Using an acute porcine model, we have previously demonstrated that continuous intrathecal drug delivery efficacy may be highly variable because of severely limited drug distribution in the cerebrospinal fluid and spinal cord. We designed this study to determine whether the limited drug distribution observed in our acute studies occurs with chronic administration as well.
METHODS: Four farm-bred pigs were implanted with intrathecal infusion pumps delivering morphine (1 mg/mL) at 20 μL per hour. Because of a programming error, 1 additional pig received intrathecal morphine at 2 μL per hour. Drug infusion continued for 14 days, during which time animal activity was unrestricted. At the end of 2 weeks the animals were anesthetized and euthanized and their spinal cords removed. The spinal cords were divided into 1-cm sections and morphine concentrations measured.
RESULTS: As with previous acute animal studies, drug distribution was extremely limited. Morphine concentration decreased exponentially as a function of distance from the catheter tip, resulting in a 5- to 10-fold decrease over a distance of only 5 to 10 cm.
CONCLUSION: Morphine distribution is very limited during chronic intrathecal delivery in ambulatory pigs, and there are significant spinal cord drug concentration gradients as a function of distance from the infusion point. Consequently, catheter tip position may be critical, particularly when infusing isobaric solutions. These data also support the hypothesis that inflammatory masses complicating chronic intrathecal opioid delivery occur at the catheter tip because limited drug distribution results in extremely high drug concentrations at that point.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212256     DOI: 10.1213/ANE.0b013e318203b7c0

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  11 in total

1.  Characteristics of distribution of morphine and metabolites in cerebrospinal fluid and plasma with chronic intrathecal morphine infusion in humans.

Authors:  Mark Wallace; Tony L Yaksh
Journal:  Anesth Analg       Date:  2012-07-19       Impact factor: 5.108

Review 2.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

3.  Intrathecal drug delivery to treat intractable neuropathic pain following Sjögren's syndrome-induced transverse myelitis: A case report.

Authors:  Ji Yeong Kim; Yong Ho Lee; Ji Young Kim; Hyun Hwa Lee; Young Hoon Kim
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

Review 4.  The American Society of Pain and Neuroscience (ASPN) Best Practices and Guidelines for the Interventional Management of Cancer-Associated Pain.

Authors:  Mansoor M Aman; Ammar Mahmoud; Timothy Deer; Dawood Sayed; Jonathan M Hagedorn; Shane E Brogan; Vinita Singh; Amitabh Gulati; Natalie Strand; Jacqueline Weisbein; Johnathan H Goree; Fangfang Xing; Ali Valimahomed; Daniel J Pak; Antonios El Helou; Priyanka Ghosh; Krishna Shah; Vishal Patel; Alexander Escobar; Keith Schmidt; Jay Shah; Vishal Varshney; William Rosenberg; Sanjeet Narang
Journal:  J Pain Res       Date:  2021-07-16       Impact factor: 3.133

Review 5.  Role of Catheter's Position for Final Results in Intrathecal Drug Delivery. Analysis Based on CSF Dynamics and Specific Drugs Profiles.

Authors:  De Andres Jose; Perotti Luciano; Villanueva Vicente; Asensio Samper Juan Marcos; Fabregat-Cid Gustavo
Journal:  Korean J Pain       Date:  2013-10-02

Review 6.  Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.

Authors:  Gladstone C McDowell; Jason E Pope
Journal:  Neuromodulation       Date:  2016-02-09

7.  Palliative care with cervical intrathecal infusion and external pump for a late-stage cancer patient with refractory pain: A case report.

Authors:  Yanxin Ju; Demin Tian; Yanqin Tan; Zhijian Fu
Journal:  Medicine (Baltimore)       Date:  2018-01       Impact factor: 1.889

Review 8.  The Pharmacology of Spinal Opioids and Ziconotide for the Treatment of Non-Cancer Pain.

Authors:  J E Pope; T R Deer; K Amirdelfan; W P McRoberts; N Azeem
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

9.  Programmable Pump for Intrathecal Morphine Delivery to Cisterna Magna: Clinical Implications in Novel Management of Refractory Pain Above Middle Thoracic Vertebrae Level Utilizing a Prospective Trial Protocol and Review.

Authors:  Chang Sun; Yu-Tong Wang; Yu-Jie Dai; Zhi-Hui Liu; Jing Yang; Zhu-Qiang Cheng; Dao-Song Dong; Cheng-Fu Wang; Guo-Li Zhao; Gui-Jun Lu; Tao Song; Yi Jin; Alan D Kaye; Farnad Imani; Kambiz Sadegi; Li-Li Sun; Yong-Hai Sun
Journal:  Anesth Pain Med       Date:  2021-06-29

10.  Intrathecal Morphine Infusion for Trigeminal Deafferentation Pain Following Percutaneous Intervention for Unexplained Facial Pain: A Case Report.

Authors:  Byung-Chul Son; Changik Lee
Journal:  Korean J Neurotrauma       Date:  2022-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.